$INSM

Bonstein Sara sold $246K of INSM

Bonstein Sara (Chief Financial Officer) sold 2,404 shares of INSMED Inc (INSM) at $102.27 ($0.25M total) on 2026-06-03.

Original reporting
SEC EDGAR · Bonstein Sara
Published Jun 5, 2026, 8:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INSM
Bearish
medium confidence
Mentioned
$INSM
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMBearishLow
01

Why it matters

The disclosure may slightly affect short-term sentiment among traders tracking insider behavior, but it does not introduce new operational, clinical, or financial information.

02

Market read

A single insider sale at a known price provides a modest sentiment datapoint without a fundamental catalyst.

03

What to watch

The filing does not state reason for sale, whether options/RSUs were involved, or whether other insiders simultaneously bought/sold—so signal-to-noise is limited.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed June 5; sale dated June 3.

Background

This is an SEC Form 4 insider transaction: INSMED CFO Sara Bonstein reported an open-market sale of 2,404 shares on June 3, filed June 5.

Company-level read

Ticker impact

$INSMBearishMedium confidence
Context

CFO Sara Bonstein sold $245.9K of INSM shares via an open-market transaction disclosed on SEC Form 4.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and quickly absorbed.

Evidence & confidence

The filing provides a concrete ownership-change datapoint, but insider sales are often routine and the article lacks new company fundamentals or guidance.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale was not pre-arranged under a 10b5-1 plan, but insider sales can still reflect diversification, taxes, or personal liquidity needs rather than bearish fundamentals.

Key entities

  • INSMED Inc

    Company whose CFO disclosed an open-market sale of common stock on SEC Form 4.

  • Sara Bonstein

    Chief Financial Officer who sold 2,404 shares at $102.27/share.

Related articles

$INSMMed

Insmed Q2 Earnings Call Highlights

Insmed (INSM) reported Q2 call highlights. It narrowed BRINSUPRI gross-to-net guidance to mid-to-high 20% and raised global peak sales to over $7B. It expects ARIKAYCE expansion filings in the U.S. and Japan, with Japan application in 2H26. TPIP peak sales estimate rose to over $6B. Cash was about $1.2B; it targets cash-flow positivity in 2027.